Resources

The Accelerating Measurable Progress and Leveraging Investments for Postpartum Hemorrhage Impact (AMPLI-PPHI) aims to dramatically reduce maternal mortality and morbidity from postpartum hemorrhage—the leading cause of maternal death worldwide.AMPLI-PPHI consortium brings together Jhpiego, PATH, and the International Federation of Gynecology and Obstetrics (FIGO) to support Ministries of Health and ensure sustainable access to quality-assured drugs.

The integrated post-validation/verification surveillance (PVS) toolkits for neglected tropical diseases (NTDs) were developed as a part of the Bill & Melinda Gates Foundation-funded NTD Surveillance Planning Toolkit project (2022 to 2025). The project aimed to develop and pilot a toolkit for assessing the capacity for integrated disease surveillance and response in low- and middle-income countries to enhance capacity to detect signals and respond to potential recrudescence of NTDs that have been eliminated.The three resources on this page summarize findings and experiences in project countries Bangladesh, Nigeria, and Senegal.

Immunization is a crucial component of primary health care, preventing 3.5-5 million deaths annually from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. It is a fundamental human right and one of the most cost-effective health investments.A recent report on the impact of inaction on immunization reveals a critical need for increased investment in immunization across 10 African countries.The ‘Who is safe: The impact of inaction on immunization’ report by WACI Health, PATH, and Gavi CSO Constituency explores the state of immunization financing and sustainability in Comoros, DRC, Ethiopia, Kenya, Malawi, Mozambique, Nigeria, Senegal, South Sudan, and Uganda.The report highlights significant challenges characterized by low public funding, high out-of-pocket payments, and substantial donor reliance. Key findings indicate inadequate investments in health and immunization led to low immunization coverage with a notable increase in zero-dose and under-immunized children, as well as higher incidences of vaccine-preventable diseases.

Noncommunicable diseases (NCDs), like diabetes, hypertension, cancers, and mental health conditions, are the leading cause of early deaths around the world. Every year, we pay the price of inaction: USD $2 trillion in lost productivity and health care costs, and 43 million lives lost to a treatable or preventable condition.Yet, there is hope: NCD solutions offer a whopping 19:1 return on investment—every step forward or faster will mean saving more lives and spending less.In today’s turbulent landscape, there is a risk that leaders might look at the problem of NCDs and think, “this can wait.” In this new position paper, we argue why this view is a missed opportunity and urge leaders to prioritize three key NCD financing actions:Increase total resources for health, including by repurposing spending on unhealthy productsMake the health budget go further with efficient win-win solutions for NCDs and beyondTrack and show the flow of NCD spending, from budget to real-world benefit

This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs with each rotavirus vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.